Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Arnaud D. Roth"'
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 3, Pp 1029-1034 (2017)
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standard therapies. Here, we describe the clinical histor
Externí odkaz:
https://doaj.org/article/c554659d7e9c489e9d55badcb4d870ee
Autor:
Mauro Delorenzi, Sabine Tejpar, Fred T. Bosman, Arnaud D. Roth, Iris M. Simon, Justin Guinney, Peter Gibbs, Stephen McLaughlin, Ian T. Jones, Peter L. Molloy, Chris Love, Robert N. Jorissen, Oliver M. Sieber, Pratyaksha Wirapati, Edoardo Missiaglia, David Barras
Purpose: Mutation of BRAF at the valine 600 residue occurs in approximately 10% of colorectal cancers, a group with particularly poor prognosis. The response of BRAF mutant colorectal cancer to recent targeted strategies such as anti-BRAF or combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906bd912048bc2f570d04428885aa140
https://doi.org/10.1158/1078-0432.c.6526311.v1
https://doi.org/10.1158/1078-0432.c.6526311.v1
Autor:
Mauro Delorenzi, Sabine Tejpar, Fred T. Bosman, Arnaud D. Roth, Iris M. Simon, Justin Guinney, Peter Gibbs, Stephen McLaughlin, Ian T. Jones, Peter L. Molloy, Chris Love, Robert N. Jorissen, Oliver M. Sieber, Pratyaksha Wirapati, Edoardo Missiaglia, David Barras
Analysis of GO processes enriched in several mTOR signatures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae8b97220cf44b9e2096b4b83789806
https://doi.org/10.1158/1078-0432.22466421
https://doi.org/10.1158/1078-0432.22466421
Autor:
Mauro Delorenzi, Sabine Tejpar, Fred T. Bosman, Arnaud D. Roth, Iris M. Simon, Justin Guinney, Peter Gibbs, Stephen McLaughlin, Ian T. Jones, Peter L. Molloy, Chris Love, Robert N. Jorissen, Oliver M. Sieber, Pratyaksha Wirapati, Edoardo Missiaglia, David Barras
Figure S1. Principal component analysis and hierarchical clustering of the 218 BRAF mutant patient cohort;Figure S2: Gene-wise and patient-wise biclustering heatmap of the 218 BRAF mutant patient cohort and comparison of BRAF mutant subtypes obtained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef2340ef1af66e9d9ae38cc413682c5
https://doi.org/10.1158/1078-0432.22466433.v1
https://doi.org/10.1158/1078-0432.22466433.v1
Autor:
Mauro Delorenzi, Sabine Tejpar, Fred T. Bosman, Arnaud D. Roth, Iris M. Simon, Justin Guinney, Peter Gibbs, Stephen McLaughlin, Ian T. Jones, Peter L. Molloy, Chris Love, Robert N. Jorissen, Oliver M. Sieber, Pratyaksha Wirapati, Edoardo Missiaglia, David Barras
Table S1: Definitions of mutation calls used in this study;Table S2: List of genes with non-zero coefficients obtained by the classifier used to categorize gene expression profiles into BM1 and BM2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::384afe503c34a81559d7ad5c625b650c
https://doi.org/10.1158/1078-0432.22466430.v1
https://doi.org/10.1158/1078-0432.22466430.v1
Autor:
Mauro Delorenzi, Sabine Tejpar, Fred T. Bosman, Arnaud D. Roth, Iris M. Simon, Justin Guinney, Peter Gibbs, Stephen McLaughlin, Ian T. Jones, Peter L. Molloy, Chris Love, Robert N. Jorissen, Oliver M. Sieber, Pratyaksha Wirapati, Edoardo Missiaglia, David Barras
This file contains the supplementary methods that either describe the methodological part related to supplementary figures or the detailed aspects for the following methods: clustering, pathway analysis, survival, methylation and proteomic analyses,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189e4c633a9a1d26747797a55e3a5fb4
https://doi.org/10.1158/1078-0432.22466412.v1
https://doi.org/10.1158/1078-0432.22466412.v1
Autor:
Michael, Montemurro, Angela, Cioffi, Julien, Dômont, Piotr, Rutkowski, Arnaud D, Roth, Roger, von Moos, Roman, Inauen, Maud, Toulmonde, Roger O, Burkhard, Claudio, Knuesli, Sebastian, Bauer, Philippe, Cassier, Heike, Schwarb, Axel, Le Cesne, Dieter, Koeberle, Daniela, Bärtschi, Daniel, Dietrich, Christine, Biaggi, John, Prior, Serge, Leyvraz
Publikováno v:
Cancer. 124(7)
Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually develop resistance and progress. Dasatinib is a potent inhibitor of BCR-ABL, KIT, and SRC family kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5885c18e24ca4f853881292c488251d
https://pubmed.ncbi.nlm.nih.gov/29315500
https://pubmed.ncbi.nlm.nih.gov/29315500
Autor:
Daniel Betticher, Walter Weder, Hans-Beat Ris, Miklos Pless, L. M. Jost, Sandra Thierstein, Roger Kann, Michael Mayer, René O. Mirimanoff, Sabine Balmer Majno, Solange Peters, Abderahim Zouhair, Shu Fang Hsu-Schmitz, Markus Furrer, Ralph A. Schmid, Arnaud D. Roth, Rolf A. Stahel, Roger Stupp
Publikováno v:
The Lancet Oncology. 10:785-793
BACKGROUND: Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be unresectable, and is managed with chemotherapy with or without radiotherapy. However, selected patients might benefit from surgical resection after neoadjuvant chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bf78629bdcbc1c49e61ae23399c6e4
https://doi.org/10.1016/s1470-2045(09)70172-x
https://doi.org/10.1016/s1470-2045(09)70172-x
Publikováno v:
Pathology-Research and Practice, Vol. 195, No 2 (1999) pp. 105-11;discussion113-4
Wilms' tumor is rare in adults. Its histology, grading and staging are identical to those in children. Investigators agree on a combined modality approach in the treatment of adult Wilms' tumor (AWT), but differ on how aggressive it should be. Some a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba73a3d08b20e4f42c96ff65f996176f
https://doi.org/10.1016/s0344-0338(99)80081-8
https://doi.org/10.1016/s0344-0338(99)80081-8
Publikováno v:
Cancer. 79:2329-2335
BACKGROUND This study was conducted to investigate the influence of therapeutic parameters on local control (LC) in the sphincter-conserving treatment of T2-T3 anal carcinoma. METHODS From 1976 to 1993, 137 patients with anal carcinoma classified as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adc13c67f438839ae9a3cb521dcd15d4
https://doi.org/10.1002/(sici)1097-0142(19970615)79:12<2329::aid-cncr6>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19970615)79:12<2329::aid-cncr6>3.0.co